Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies.
van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES, Tikkanen MJ, Wareham NJ, Faergeman O, Olsson AG, Pedersen TR, Khaw KT, Kastelein JJ. van der Steeg WA, et al. J Am Coll Cardiol. 2008 Feb 12;51(6):634-42. doi: 10.1016/j.jacc.2007.09.060. J Am Coll Cardiol. 2008. PMID: 18261682 Free article. Clinical Trial.
Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.
Klerkx AH, El Harchaoui K, van der Steeg WA, Boekholdt SM, Stroes ES, Kastelein JJ, Kuivenhoven JA. Klerkx AH, et al. Among authors: van der steeg wa. Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):706-15. doi: 10.1161/01.ATV.0000205595.19612.c9. Epub 2006 Jan 26. Arterioscler Thromb Vasc Biol. 2006. PMID: 16439711 Review.
Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study.
El Harchaoui K, van der Steeg WA, Stroes ES, Kuivenhoven JA, Otvos JD, Wareham NJ, Hutten BA, Kastelein JJ, Khaw KT, Boekholdt SM. El Harchaoui K, et al. Among authors: van der steeg wa. J Am Coll Cardiol. 2007 Feb 6;49(5):547-53. doi: 10.1016/j.jacc.2006.09.043. Epub 2007 Jan 22. J Am Coll Cardiol. 2007. PMID: 17276177 Free article.
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.
Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, Deedwania P, Olsson AG, Boekholdt SM, Demicco DA, Szarek M, LaRosa JC, Pedersen TR, Grundy SM; TNT Study Group; IDEAL Study Group. Kastelein JJ, et al. Among authors: van der steeg wa. Circulation. 2008 Jun 10;117(23):3002-9. doi: 10.1161/CIRCULATIONAHA.107.713438. Epub 2008 Jun 2. Circulation. 2008. PMID: 18519851
The role of CETP inhibition in dyslipidemia.
El Harchaoui K, van der Steeg WA, Stroes ES, Kastelein JJ. El Harchaoui K, et al. Among authors: van der steeg wa. Curr Atheroscler Rep. 2007 Aug;9(2):125-33. doi: 10.1007/s11883-007-0008-5. Curr Atheroscler Rep. 2007. PMID: 17877921 Review.
Inherited disorders of HDL metabolism and atherosclerosis.
Hovingh GK, de Groot E, van der Steeg W, Boekholdt SM, Hutten BA, Kuivenhoven JA, Kastelein JJ. Hovingh GK, et al. Curr Opin Lipidol. 2005 Apr;16(2):139-45. doi: 10.1097/01.mol.0000162318.47172.ef. Curr Opin Lipidol. 2005. PMID: 15767853 Review.
Role of CETP inhibitors in the treatment of dyslipidemia.
van der Steeg WA, Kuivenhoven JA, Klerkx AH, Boekholdt SM, Hovingh GK, Kastelein JJ. van der Steeg WA, et al. Curr Opin Lipidol. 2004 Dec;15(6):631-6. doi: 10.1097/00041433-200412000-00002. Curr Opin Lipidol. 2004. PMID: 15529021 Review.
18 results